Pune, Maharshtra-based Serum Institute of India (SII) invested over $68 million in UK-based Oxford Biomedica plc, a gene and cell therapy company specializing in the development of gene-based medicines. Serum Life Sciences Ltd, a unit of SII, will pick up a 3.9% stake in Oxford Biomedica as part of the...
AstraZeneca Launches a Clinical Data and Insights Division in India
British-Swedish multinational pharmaceutical and biotechnology company AstraZeneca set up a clinical data and insights (CDI) division in Bangalore for data-related management of its clinical trials. The CDI is a critical advancement that will support a growing global portfolio and build on internal data expertise. It will function across therapy areas...
Serum Institute Preps for Phase 3 Trial of Covid Vaccine
Five sites across India are ready for the third and final phase of human trials of the Oxford-AstraZeneca COVID-19 vaccine, Department of Biotechnology Secretary Renu Swarup said on Monday. The Serum Institute of India, the largest vaccine maker in the world, has been chosen by Oxford and its partner AstraZeneca to...
Global Captive Centers Outpace Indian I.T. Companies in Hiring
For the first time since 2008, global in-house center (GIC) hires by foreign companies overtook the number of people hired by India's IT services and back-office companies. About 1,100 GICs now employ 900,000 people in India. "While hiring by pure-play India-based technology services players was muted, Indian GICs have hired...